Arrowhead Pharmaceuticals Inc. (ARWR) Tops Q2 EPS by 320c
Tweet
Share
E-mailGet Alerts ARWR Hot Sheet
Price: $83.99 +4.41%
Revenue Growth %: +89.8%
Financial Fact:
TOTAL OTHER INCOME (EXPENSE): -79.26K
Today's EPS Names:
CRMT, More
Revenue Growth %: +89.8%
Financial Fact:
TOTAL OTHER INCOME (EXPENSE): -79.26K
Today's EPS Names:
CRMT, More
Join SI Premium – FREE
Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) reported Q2 EPS of $2.75, $3.20 better than the analyst estimate of ($0.45). Revenue for the quarter came in at $542.71 million versus the consensus estimate of $127.9 million.
For earnings history and earnings-related data on Arrowhead Pharmaceuticals Inc. (ARWR) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Trump said he was unaware of his earnings from crypto
- Trump: 40-60% of chip manufacturing will be in the U.S. - CNBC Interview
- Raymond James Upgrades Aecon Group (ARE:CN) (AEGXF) to Outperform
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
